Research And Development Tenders

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Allergen Extract from Timothy Grass Polle, Atc Code: V01aa02 for the Period from August 1St, 2023 to July 31St, 2025

Completion of a Non-Excl. Discount Agreement According to § 130A Para. 8 Sgb V for Colistimethate Sodium, Atc Code: J01xb01 for the Period from August 1St, 2023 to July 31St, 2025

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Alitretinoin (Atc Code According to Who: D11ah04)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Oh-Biologika-2023-18

Oh-Biologika-2023-17 - Bevacizumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Alitretinoin (Atc Code According to Who: D11ah04)

Conclusion of a Non-Exclusive Framework Agreement for Control Tests in Road Construction and further Building Material Tests in the Open House Procedure of the Northern Bavaria Branch

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Omalizumab (R03dx05) as Part of a So-Called Open House Model.